Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/5/2023 | $3.50 → $2.29 | Buy → Hold | Jefferies |
| 9/25/2023 | $5.00 → $2.50 | Buy → Hold | Canaccord Genuity |
| 2/1/2022 | $12.00 | Buy | Stifel |
| 12/14/2021 | $19.00 | Buy | Canaccord Genuity |
| 12/10/2021 | $16.00 | Buy | Jefferies |
| 11/23/2021 | $18.00 | Outperform | Cowen & Co. |
https://www.businesswire.com/news/home/20240104250020/en/
Jefferies downgraded SomaLogic from Buy to Hold and set a new price target of $2.30 from $3.50 previously
Canaccord Genuity downgraded SomaLogic from Buy to Hold and set a new price target of $2.50 from $5.00 previously
Stifel initiated coverage of SomaLogic with a rating of Buy and set a new price target of $12.00
15-12G - SomaLogic, Inc. (0001837412) (Filer)
EFFECT - SomaLogic, Inc. (0001837412) (Filer)
EFFECT - SomaLogic, Inc. (0001837412) (Filer)
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
Appoints Eliot M. Lurier, CPA, as Interim Chief Financial Officer Reaffirms 2023 Financial Guidance BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC), a leader in proteomics technology, today announced a Chief Financial Officer transition. Eliot M. Lurier, CPA, is joining the company as Interim CFO while the Company conducts a search for a permanent CFO. Shaun Blakeman has left the company, effective June 5, 2023. Mr. Lurier has over 35 years of experience in financial and leadership positions across the life science industry. He will report directly to the Interim CEO and immediately embed within the finance organization to ensure a seamless transiti
BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ:SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the company's Board of Directors. The current Chair, Chuck Lillis, will remain on the board. Changes are effective as of today, October 17, 2022. Mr. Cox brings over thirty years of experience in the life sciences and biopharmaceuticals industry to his expanded position as Executive Chair of the Board. Mr. Cox was the President and CEO of Foundation Medicine from early 2017 through the acquisition by Roche, valuing Foundation Medicine at $5.3 bill
SC 13G/A - SomaLogic, Inc. (0001837412) (Subject)
SC 13G/A - SomaLogic, Inc. (0001837412) (Subject)
SC 13D/A - SomaLogic, Inc. (0001837412) (Subject)
Continues to Recommend Stockholders Vote "FOR" Pending Merger ISS has Dismissed Madryn's Misleading Claims and Reaffirms that Stockholders Vote "FOR" the Merger BOULDER, Colo., Dec. 29, 2023 /PRNewswire/ -- SomaLogic, Inc. (NASDAQ:SLGC) ("the Company"), a leader in proteomics technology, today sent the following open letter to stockholders reiterating the Board's belief that the proposed transaction between SomaLogic and Standard BioTools is in the best interest of all stockholders. The full text of the letter is as follows: Dear Fellow Stockholders, We firmly believe that the value-maximizing transaction with Standard BioTools is the best path forward for SomaLogic and all of its stockhold
BOULDER, Colo., Dec. 22, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that Institutional Shareholder Services ("ISS") has recommended that SomaLogic stockholders vote "FOR" the pending merger with Standard BioTools at the company's Special Meeting of Stockholders to be held on January 4, 2024. In its "FOR" recommendation to SomaLogic stockholders, ISS noted1: The strategic rationale of combining two sub-scale companies in order to slow down cash burn and accelerate the path to profitability appears reasonable, particularly given the apparent overlap in the two companies' offerings and the estimated synergies in this transaction.…the all-sto
Combination Builds Scale and Accelerates Path to Profitability, Unlocking Significant Potential Value for SomaLogic Stockholders Madryn's Concerns are Not Based on Facts, and Madryn Selectively Ignores Risks in a Standalone Strategy and Potential Benefits of the Merger Urges Stockholders to Vote "FOR" Merger Ahead of Special Meeting of Stockholders on January 4, 2024 BOULDER, Colo., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC) today issued an open letter to stockholders highlighting the value maximizing merger entered into with Standard BioTools (NASDAQ:LAB) on October 4, 2023. The Company also filed an investor presentation, which can be found on th
Data to showcase PROphet® platform's machine learning models for predicting therapeutic benefit and immune-related adverse events in non-small cell lung cancer patients treated with immunotherapy BINYAMINA, Israel and CARY, N.C., March 5, 2024 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced it will be presenting new results at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 5-10, 2024. The oral presentation will feature insights from the company's PROPHETIC trial, to be delivered by Prof. Jarushka Naidoo, consultant medical oncologi
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic (NASDAQ:SLGC) at its Special Meeting of Stockholders. "We are pleased with the outcome of today's Special Meeting and thank our stockholders for their support for this merger," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Together with SomaLogic, we will have an expanded platform to better serve our customers and we be
Stockholder Approval Represents Key Milestone Toward Completion of Standard BioTools Transaction Combination Will Create a Diversified Leader in Life Sciences Tools BOULDER, Colo., Jan. 4, 2024 /PRNewswire/ -- SomaLogic, Inc. (NASDAQ:SLGC) ("the Company"), a leader in proteomics technology, today announced that, based on the preliminary vote count provided by its proxy solicitors following the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today, SomaLogic stockholders voted to approve the transaction with Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools"). The SomaLogic Board of Directors issued the following statement: We are grateful for the suppor
4 - SomaLogic, Inc. (0001837412) (Issuer)
4 - SomaLogic, Inc. (0001837412) (Issuer)
4 - SomaLogic, Inc. (0001837412) (Issuer)